Inabata France

About Inabata France

With more than 40 years of history in API manufacturing, PHARMASYNTHESE belongs to the Japanese Group INABATA through its French subsidiary INABATA France.GMP Manufacturing and Distribution of:- Active Pharmaceutical Ingredients- Advanced Intermediates- Specialities

Certifications
  • FR
  • 2015
    On CPHI since
  • 2
    Certificates
  • 25 - 49
    Employees
Company types
Manufacturer/Innovator
Primary activities
API Producer
Contact info
  • 6-8, Rue du 4 Septembre, Immeuble Le Rubix, Issy-Les-Moulineaux, 92130 , Wissous, France
Meet us at

CPHI Milan 2024

Fiera Milano, Italy
08 Oct 2024 - 10 Oct 2024

Products from Inabata France (5)

  • SERTACONAZOLE NITRATE

    Product SERTACONAZOLE NITRATE

    PHARMASYNTHESE - INABATA offers a wide range of products which includes Sertaconazole Nitrate. It is useful for the treatment of antifungal. Contact us for more information.             CEP obtained in 2017 :  R0-CEP 2015-066-Rev 01
  • AMOROLFINE HCl

    Product AMOROLFINE HCl

    PHARMASYNTHESE - INABATA offers a wide range of products which includes amorolfine hcl. It is useful for the treatment of antifungal. Contact us for more information.                        CEP obtained in 2018 : R0-CEP 2016-312-Rev 00
  • DIBUCAINE HCl

    Product DIBUCAINE HCl

    Inabata France offers a wide range of active pharmaceutical ingredients which includes dibucaine hcl. It belongs to anesthesic category. Contact us for more information.CEP obtained in 2007 : R1-CEP 2007-117-Rev 01
  • ESCULINE

    Product ESCULINE

    Inabata France offers a wide range of active pharmaceutical ingredients which includes esculine. It belongs to antiphlogistic category. Contact us for more information.DMF available
  • FENTICONAZOLE NITRATE

    Product FENTICONAZOLE NITRATE

    PHARMASYNTHESE - INABATA offers a wide range of products which includes Fenticonazole Nitrate. It is useful for the treatment of antifungal. 
    Contact us for more information.             
    CEP obtained in 2017 :   R0-CEP 2015-157-Rev 02